Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial.
Bruno FrancoisEmmanuelle MercierCéline GonzalezKarim AsehnouneSaad NseirMaud FiancetteArnaud DesachyGaëtan PlantefèveFerhat MezianiPaul-André de LamePierre-François Laterrenull nullPublished in: Intensive care medicine (2018)
Adjunctive treatment of severe S. aureus HABP with anti-staphylococcal mAbs appears feasible and suggests some clinical benefits, but larger randomized studies are needed to better define its safety and efficacy.
Keyphrases
- staphylococcus aureus
- monoclonal antibody
- endothelial cells
- open label
- phase iii
- induced pluripotent stem cells
- double blind
- clinical trial
- phase ii
- pluripotent stem cells
- placebo controlled
- early onset
- study protocol
- randomized controlled trial
- escherichia coli
- cystic fibrosis
- mechanical ventilation
- pseudomonas aeruginosa
- respiratory failure